Compare Verisign, Inc. (VRSN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Verisign, Inc. trades at $284.92 (market cap $26.00B), while Vertex Pharmaceuticals Incorporated trades at $528.32 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.2× Verisign, Inc.'s market cap, and Verisign, Inc. pays a 1.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VRSN | VRTX | |
|---|---|---|
Market Cap | $26.00B | $134.25B |
Sector | Technology | Health |
52-Week High | $310.00 | $529.65 |
52-Week Low | $211.49 | $376.62 |
Enterprise Value | $27.31B | $128.37B |
Dividend Yield | 1.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VeriSign (VRSN) trades at $293.34, down 0.41% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with record domain registrations and 6% revenue growth, maintaining robust profit margins near 50%. Recent delegation of .web domain and AI-driven registration growth provide positive catalysts.
The stock offers 9% upside to consensus price target of $320 with 60% analyst buy ratings. Key risks include contract renewals and premium valuation at 31x P/E. Strong cash flow generation and dividend payments support shareholder returns amid stable internet infrastructure demand.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
